Legal & General Group Plc Purchases New Shares in Omnicell, Inc. $OMCL

Legal & General Group Plc acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) during the second quarter, HoldingsChannel reports. The fund acquired 173,267 shares of the company’s stock, valued at approximately $7,194,000.

Several other institutional investors have also added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company purchased a new stake in shares of Omnicell in the 2nd quarter worth about $928,000. Algert Global LLC increased its position in shares of Omnicell by 147.9% during the second quarter. Algert Global LLC now owns 25,392 shares of the company’s stock valued at $1,054,000 after buying an additional 15,150 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Omnicell in the second quarter worth about $6,560,000. Elevation Point Wealth Partners LLC bought a new position in Omnicell in the second quarter worth about $251,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new stake in Omnicell in the second quarter worth about $105,000. 97.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Zacks Research downgraded Omnicell from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Wells Fargo & Company lowered their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Piper Sandler restated an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a research note on Monday, August 24th. Finally, Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.86.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $34.71 on Thursday. The company has a 50 day simple moving average of $39.55 and a two-hundred day simple moving average of $39.29. Omnicell, Inc. has a fifty-two week low of $29.06 and a fifty-two week high of $55.00. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of 41.32, a P/E/G ratio of 0.87 and a beta of 0.97. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. The firm had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Analysts expect that Omnicell, Inc. will post 1.41 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.